Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics
<i>Fasciola hepatica</i>, the causative agent of fasciolosis, is a global threat to public health, animal welfare, agricultural productivity, and food security. In the ongoing absence of a commercial vaccine, independent emergences of anthelmintic-resistant parasite populations worldwide...
Main Authors: | Clare F. Collett, Russell M. Morphew, David Timson, Helen C. Phillips, Peter M. Brophy |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/15/3477 |
Similar Items
-
In vitro biomarker discovery in the parasitic flatworm Fasciola hepatica for monitoring chemotherapeutic treatment
by: Russell M. Morphew, et al.
Published: (2014-06-01) -
In Vtro Effects of Triclabendazole (TCBZ) on the Excretory-Secretory Products (ESP) of Fasciola Spp Parasites
by: Taghi Golmohamdi, et al.
Published: (2012-03-01) -
In vitro Effects of Triclabendazole (TCBZ) on the Excretory-Secretory Products (ESP) of Fasciola spp Parasites
by: Ali Farahnak, et al.
Published: (2012-03-01) -
Study of Triclabendazole (TCBZ) Effect on Aspartate Transaminase (AST) Activity of Fasciola gigantica Parasite and Liver Enzyme Activity Assay
by: Shima Shafaei, et al.
Published: (2015-10-01) -
Fasciola Hepatica Induced Hepatic Abscess Treated with Triclabendazole
by: Hyun Joon Park, et al.
Published: (2021-01-01)